课题基金 / 基金详情

University of Colorado Southwest Oncology Group

University of Colorado Southwest Oncology Group
科罗拉多大学西南肿瘤学组
批准号:
8410589
负责人:
ANTHONY D ELIAS
金额:
$6.6万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-01-21 至 2014-12-31

项目摘要

项目成果

ANTHONY D ELIAS的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 科罗拉多大学癌症中心(UCCC)是落基山脉地区唯一一家由NCI指定的综合癌症中心,该地区人口约为800万。在过去的四年中,NCI赞助的研究组合一直稳定在约4000万美元,不包括核心赠款。门诊就诊人数和现在临床活跃的教师人数都在增加,我们希望这将转化为临床试验患者人数的显着增加。UCCC是科罗拉多丹佛大学(UCD)内的一个“矩阵”中心,并已完成搬迁到旧菲茨西蒙斯陆军基地(安舒茨医学校区)的新校区。其主要临床护理中心包括科罗拉多大学医院(UGH)、丹佛退伍军人管理医疗中心(DVAMC)、丹佛健康医疗中心(DHMC)和丹佛儿童医院(TCH)。我们也有越来越多的外展诊所直接由我们的教师,包括蒙特罗斯医院在蒙特罗斯,谷景医院在格伦伍德泉,和维尔谷医疗中心在爱德华兹。其他项目正在开发中,包括阿拉莫萨。我们有附属机构(CGOP),包括科罗拉多斯普林斯的纪念医院和柯林斯堡的波德谷医疗中心。我们的U10和UGOP资助的西南肿瘤组(SWOG)成员实现了我们癌症中心的许多目标,为科罗拉多的公民提供广泛的创新II期和III期治疗和化学预防试验。这笔赠款为在主要机构和外展诊所及附属机构进行临床试验所需的监测和监督提供部分支持。反过来,我们的教师也提供了强有力的行政和科学领导,特别是在GU和肺部委员会以及手术、病理和放射治疗模式方面,正如服务或主持SWOG委员会所记录的那样,担任II/III期SWOG小组试验的PI,包括PCPT和选择,进行试点,为后续SWOG试验提供基础,然后积累受试者。我们预计在下一个赠款周期,乳腺癌和GI委员会的活动将显著增加。临床试验代表了癌症治疗和预防的最新技术,应该广泛提供给科罗拉多的公民。 相关性:临床试验,特别是III期研究,推动了进展,并建立了新的护理标准(SOC),然后必须加以改进。大多数III期肿瘤学试验证明实验组上级先前的SOC,这并非偶然,但进展是渐进的。这笔赠款提供了必要的资源,以支持我们的癌症中心和落基山脉地区周围的多个地点的这些临床试验。获得临床试验是卓越医疗保健的关键。 主要研究者: 博士Elias是UCCC的医学教授和临床科学副主任,也是科罗拉多大学乳腺癌临床项目的医学主任。在过去的6年里,他一直是UCCC SWOG U10的PI。他完全有资格担任他的职务。 人类受试者保护(简历):可接受 没有明显的担忧。 女性入选(简历):可接受 没有明显的担忧。 列入少数群体名单(简历):可接受 没有明显的担忧。 入选儿童(简历):可接受 入组的受试者通常为18岁或以上。 总体建议: 此应用程序的评级为33,建议提供六年的支持。
英文摘要
DESCRIPTION (provided by applicant): The University of Colorado Cancer Center (UCCC) is the only NCI-designated Comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. Over the past four years, the NCI sponsored research portfolio has remained stable at about $40 million, excluding the Core grant. Outpatient visits and now clinically active faculty are growing, which we hope will translate into a marked increase in patient accruals to clinical trials. UCCC is a "matrix" center within the University of Colorado Denver (UCD) and has completed its move to its new campus at the old Fitzsimons Army base (Anschutz Medical Campus). Its major clinical care centers include the University of Colorado Hospital (UGH), Denver Veterans Administration Medical Center (DVAMC), Denver Health Medical Center (DHMC), and The Children's Hospital Denver (TCH). We also have a growing number of outreach clinics staffed directly by our faculty including Montrose Hospital in Montrose, Valley View Hospital in Glenwood Springs, and Vail Valley Medical Center in Edwards. Others are in development including at Alamosa. We have affiliates (CGOPs) including Memorial Hospital in Colorado Springs and Poudre Valley Medical Center in Fort Collins. Our U10- and UGOP- funded membership in the Southwest Oncology Group (SWOG) fulfills many of the goals of our Cancer Center by providing broad access to innovative phase II and III treatment and chemoprevention trials to the citizens of Colorado. This grant provides partial support for the needed monitoring and oversight to run clinical trials at the main institutions and outreach clinics and affiliates. Our faculty, in turn, have provided strong administrative and scientific leadership, particularly in the GU and Lung Committees and the Surgery, Pathology and Radiation Therapy modalities as documented by serving or chairing SWOG committees, serving as PIs for phase ll/lll SWOG group trials including PCPT and SELECT, conducting pilots to provide the basis for subsequent SWOG trials, and then accruing subjects. We expect significantly increased activity in the Breast and Gl committees during the next grant cycle. Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado. RELEVANCE: Clinical trials, especially phase III studies, drive progress and establish new standards of care (SOC) that must then be improved on. It is no accident that the majority of phase III oncology trials prove that the experimental arm is superior to the previous SOC, but progress is incremental. This grant provides essential resources to support these clinical trials to our Cancer Center and to multiple sites around the Rocky Mountain region. Access to clinical trials is crucial for excellence in health care. PRINCIPAL INVESTIGATOR: Dr. Elias is a Professor of Medicine and Associate Director for Clinical Sciences for the UCCC as well as the Medical Director of the Breast Cancer Clinical Program at the University of Colorado. He has been the PI for the UCCC SWOG U10 for the past 6 years. He is fully qualified for his position. PROTECTION OF HUMAN SUBJECTS (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF WOMEN PLAN (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF MINORITIES PLAN (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF CHILDREN PLAN (Resume): ACCEPTABLE Enrolled subjects are generally 18 years of age or older. OVERALL RECOMMENDATION: This application is rated 33 and is recommended for six years of support.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
铂和米托蒽醌治疗转移性前列腺癌的 II 期研究:西南肿瘤小组研究。
DOI: 10.1016/s0959-8049(05)80080-2
发表时间: 1992
期刊: European journal of cancer (Oxford, England : 1990)
影响因子: --
作者: [Osborne,CK, Blumenstein,BA, Crawford,ED, Weiss,GR, Bukowski,RM, Larrimer,NR]
通讯作者: Larrimer,NR
Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
高剂量间歇性白细胞介素 2 治疗转移性肾细胞癌的 II 期试验:西南肿瘤学小组的一项研究。
DOI: 10.1093/jnci/82.2.143
发表时间: 1990
期刊: Journal of the National Cancer Institute
影响因子: --
作者: [Bukowski,RM, Goodman,P, Crawford,ED, Sergi,JS, Redman,BG, Whitehead,RP]
通讯作者: Whitehead,RP
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
13-顺式视黄酸加干扰素 α-2a 治疗晚期阴茎癌的 II 期研究:东部肿瘤合作组研究 (E3893)。
DOI: 10.1081/cnv-120016402
发表时间: 2003
期刊: Cancer investigation
影响因子: 2.4
作者: [Skeel,RolandT, Huang,Jie, Manola,Judith, Wilding,George, Dreicer,Robert, Walker,Paul, Muggia,Franco, Crawford,EDavid, Dutcher,JaniceP, Loehrer,PatrickJ]
通讯作者: Loehrer,PatrickJ
DOI: 10.1016/0090-4295(92)90247-t
发表时间: 1992
期刊: Urology
影响因子: 2.1
作者: [Crawford,ED, Goodman,P, Nabors,WL, Stephens,RL, Khan,K, Pass,LM, Smith,AY, Christie,DW]
通讯作者: Christie,DW
共 14 条
    NCI National Clinical Trials Network - Lead Academic Participant Sites
    • 批准号:
      10359729
    • 项目类别:
    • 资助金额:
      $65.06万
    • 财政年份:
      2019
    • 负责人:
      ANTHONY D ELIAS
    • 依托单位:
    NCI National Clinical Trials Network - Lead Academic Participant Sites
    • 批准号:
      9903262
    • 项目类别:
    • 资助金额:
      $65.06万
    • 财政年份:
      2019
    • 负责人:
      ANTHONY D ELIAS
    • 依托单位:
    NCI National Clinical Trials Network - Lead Academic Participant Sites
    • 批准号:
      10581547
    • 项目类别:
    • 资助金额:
      $65.06万
    • 财政年份:
      2019
    • 负责人:
      ANTHONY D ELIAS
    • 依托单位:
    University of Colorado NTCN Lead Academic Participating Site (LAPS)
    • 批准号:
      8605721
    • 项目类别:
    • 资助金额:
      $76.9万
    • 财政年份:
      2014
    • 负责人:
      ANTHONY D ELIAS
    • 依托单位:
    国内基金
    海外基金
    层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
    • 批准号:
      2021JJ40433
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2021
    • 负责人:
      孙磊
    • 依托单位:
    寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
    • 批准号:
      32001603
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      段真珍
    • 依托单位:
    AREA国际经济模型的移植.改进和应用
    • 批准号:
      18870435
    • 项目类别:
      面上项目
    • 资助金额:
      2.0万元
    • 批准年份:
      1988
    • 负责人:
      史树中
    • 依托单位: